What Is Lupus? The Autoimmune Disease That Attacks Everything

What Is Lupus?

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system attacks the body's own tissues, causing inflammation and damage to virtually any organ — joints, skin, kidneys, heart, lungs, brain, and blood cells. The word "systemic" reflects its body-wide nature.

Lupus affects approximately 1.5 million Americans and 5 million people worldwide. It disproportionately affects women of childbearing age (90% of patients are female), and is more common and more severe in African American, Hispanic, Asian, and Native American women compared to Caucasian women — racial disparities that reflect both genetic and social determinants of health.

Why Lupus Happens

In lupus, the immune system fails to distinguish self from non-self. It produces autoantibodies (antibodies against the body's own cells and proteins) — particularly anti-double-stranded DNA (anti-dsDNA) and anti-Smith (anti-Sm) antibodies, which are characteristic of lupus. These autoantibodies form immune complexes that deposit in tissues, triggering complement activation and chronic inflammation.

The exact trigger is unknown, but lupus results from a complex interaction of:

• Genetics: Over 100 genetic risk loci identified; concordance in identical twins of ~25–50%, indicating genes are necessary but not sufficient
• Hormones: Estrogen appears to promote autoimmunity, explaining the strong female predominance. Lupus often flares during pregnancy and at ovulation.
• Environment: Ultraviolet light is the most documented trigger (explaining photosensitivity). Epstein-Barr virus infection, smoking, and certain drugs (drug-induced lupus) are also implicated.

Symptoms: The Great Imitator

Lupus is notoriously difficult to diagnose because it can mimic dozens of other conditions and manifests differently in each patient. Average time from first symptoms to diagnosis: 6 years. Common presentations:

• Constitutional: Fatigue (in nearly all patients — often severe), fever, weight loss
• Musculoskeletal: Joint pain and swelling in 90%+ — symmetric, migratory; joint damage less common than in rheumatoid arthritis
• Skin: The classic "butterfly rash" (malar rash) — a flat red rash across the cheeks and nose bridge, shaped like a butterfly — present in ~50%; photosensitivity in ~80%; discoid rash (scarring); oral ulcers
• Renal (lupus nephritis): Kidney involvement in 50–60%, ranging from mild to severe; leading cause of lupus-related death and disability
• Hematologic: Anemia (hemolytic or chronic inflammation), low platelets (thrombocytopenia), low white blood cells
• Cardiovascular: Accelerated atherosclerosis; pericarditis; Libman-Sacks endocarditis
• Neuropsychiatric: Cognitive dysfunction ("lupus fog"), headaches, seizures, psychosis
• Serositis: Pleuritis (lung lining inflammation), pericarditis (heart lining inflammation)

Diagnosis

The ACR/EULAR 2019 Classification Criteria use a weighted scoring system based on clinical and immunological features. Key laboratory findings: positive ANA (antinuclear antibody) — present in ~98% (but not specific, also positive in healthy people); anti-dsDNA — more specific; low complement (C3, C4); blood count abnormalities. Kidney biopsy is important to characterize lupus nephritis severity.

Treatment

Lupus treatment depends on which organs are affected and disease severity:

• Hydroxychloroquine (Plaquenil): The backbone of lupus therapy — recommended for nearly all patients. Anti-malarial drug that reduces flare frequency, prevents organ damage, improves survival, and reduces cardiovascular risk. Requires regular eye monitoring for rare retinal toxicity.
• NSAIDs and corticosteroids: For acute flares — effective but corticosteroids carry significant long-term side effects (osteoporosis, infection, weight gain, diabetes)
• Immunosuppressants: Mycophenolate mofetil, azathioprine, cyclophosphamide for organ-threatening disease (particularly lupus nephritis)
• Biologics: Belimumab (Benlysta) — first biologic approved specifically for lupus (2011); anifrolumab (2021) targets the interferon pathway. Voclosporin approved for lupus nephritis (2021).

Despite the lack of a cure, modern treatment has transformed lupus outcomes dramatically. Survival rates have improved from 50% at 5 years (1950s) to 80–90% at 20 years with modern treatment.